Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | BYON4413 |
Synonyms | |
Therapy Description |
BYON4413 is an antibody-drug conjugate (ADC) targeting IL3RA (CD123), which potentially decreases tumor growth (Blood (2023) 142 (Supplement 1): 2795). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BYON4413 | BYON-4413|BYON 4413 | BYON4413 is an antibody-drug conjugate (ADC) targeting IL3RA (CD123), which potentially decreases tumor growth (Blood (2023) 142 (Supplement 1): 2795). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06359002 | Phase I | BYON4413 | Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms. | Recruiting | NLD | ESP | BEL | 0 |